Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 6/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14788877 | 1.00 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19HTTL3MBTL1 | |
| SCHEMBL2721300 | 0.90 | CYP1A2 (0.68) | CYP1A2CYP2C9CYP2C19HTTL3MBTL1 | |
| SCHEMBL14777839 | 0.90 | CYP1A2 (0.60) | CYP1A2CYP2C9CYP2C19HTTL3MBTL1 | |
| SCHEMBL2721298 | 0.90 | CYP1A2 (0.68) | CYP1A2CYP2C9CYP2C19HTTL3MBTL1 | |
| SCHEMBL14777840 | 0.90 | CYP1A2 (0.60) | CYP1A2CYP2C9CYP2C19HTTL3MBTL1 | |
| SCHEMBL5916340 | 0.88 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19HTTL3MBTL1 | |
| SCHEMBL20473230 | 0.88 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19HTTL3MBTL1 | |
| SCHEMBL718684 | 0.88 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19HTTL3MBTL1 | |
| SCHEMBL22382062 | 0.88 | CTSK (0.48) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL19396315 | 0.86 | CTSK (0.47) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8784774-B2 | Labeled molecular imaging agents and methods of use | GENERAL ELECTRIC COMPANY (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130071332-A1 | LABELED MOLECULAR IMAGING AGENTS AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071332-A1 | LABELED MOLECULAR IMAGING AGENTS AND METHODS OF USE | SLC7A11, GLS, SLC3A2 | CYP1A2 4843/4885CYP2C9 4800/4885CYP2C19 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.